Terence Flynn
Stock Analyst at Morgan Stanley
(4.14)
# 492
Out of 5,049 analysts
212
Total ratings
64.15%
Success rate
9.08%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Equal-Weight | $333 → $329 | $314.52 | +4.60% | 10 | Nov 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $98 → $100 | $85.61 | +16.82% | 18 | Nov 3, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $178 → $190 | $186.69 | +1.77% | 25 | Oct 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $15 | $12.78 | +17.37% | 6 | Oct 14, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $33 → $32 | $24.84 | +28.82% | 19 | Oct 10, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $55 → $54 | $41.04 | +31.58% | 13 | Oct 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $133 → $131 | $102.65 | +27.62% | 5 | Oct 10, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $439 → $438 | $417.08 | +5.02% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $328 → $435 | $454.55 | -4.30% | 11 | Oct 10, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,028 → $1,023 | $939.37 | +8.90% | 21 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $4.78 | +360.25% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $54 | $8.88 | +508.11% | 3 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $255 | $218.08 | +16.93% | 18 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $34 | $46.38 | -26.68% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $9.83 | +11.90% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $19.76 | +11.36% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $6.61 | +51.29% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $56.94 | -43.80% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $12.42 | -11.43% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $33.08 | +256.71% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.41 | +231.95% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $156.20 | +179.13% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $436.72 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.00 | - | 1 | Jul 21, 2017 |
Amgen
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $333 → $329
Current: $314.52
Upside: +4.60%
Merck & Co.
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $100
Current: $85.61
Upside: +16.82%
Johnson & Johnson
Oct 15, 2025
Maintains: Equal-Weight
Price Target: $178 → $190
Current: $186.69
Upside: +1.77%
Nurix Therapeutics
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $12.78
Upside: +17.37%
Pfizer
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $33 → $32
Current: $24.84
Upside: +28.82%
Royalty Pharma
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $41.04
Upside: +31.58%
BioNTech SE
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $102.65
Upside: +27.62%
Vertex Pharmaceuticals
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $439 → $438
Current: $417.08
Upside: +5.02%
United Therapeutics
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $454.55
Upside: -4.30%
Eli Lilly and Company
Oct 3, 2025
Maintains: Overweight
Price Target: $1,028 → $1,023
Current: $939.37
Upside: +8.90%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $4.78
Upside: +360.25%
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $8.88
Upside: +508.11%
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $218.08
Upside: +16.93%
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $46.38
Upside: -26.68%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $9.83
Upside: +11.90%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $19.76
Upside: +11.36%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $6.61
Upside: +51.29%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $56.94
Upside: -43.80%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $12.42
Upside: -11.43%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $33.08
Upside: +256.71%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.41
Upside: +231.95%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $156.20
Upside: +179.13%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $436.72
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.00
Upside: -